-
Acta Dermato-venereologica May 2023
Topics: Humans; Purpura; Skin Abnormalities
PubMed: 37165684
DOI: 10.2340/actadv.v103.4540 -
BMJ Case Reports Jan 2021
Topics: Female; Humans; Middle Aged; Pigmentation Disorders; Pruritus; Purpura
PubMed: 33462064
DOI: 10.1136/bcr-2020-240052 -
Actas Dermo-sifiliograficas May 2023
Topics: Humans; Purpura; Necrosis
PubMed: 37028472
DOI: 10.1016/j.ad.2023.04.004 -
Actas Dermo-sifiliograficas May 2023
Topics: Humans; Purpura; Necrosis
PubMed: 35843292
DOI: 10.1016/j.ad.2021.07.024 -
Cleveland Clinic Journal of Medicine Jan 2024
Topics: Humans; Endocarditis, Bacterial; Endocarditis; Purpura
PubMed: 38167396
DOI: 10.3949/ccjm.91a.23041 -
Blood Aug 1982Disseminated intravascular coagulation (DIC) is caused by a variety of underlying disorders, and criteria for diagnosis are not well defined. However, the most helpful... (Review)
Review
Disseminated intravascular coagulation (DIC) is caused by a variety of underlying disorders, and criteria for diagnosis are not well defined. However, the most helpful are a low platelet count, positive plasma protamine test, and fibrinogen and fibrin degradation product levels viewed in the context of the patient's underlying disease. The cornerstone of therapy is prompt treatment of the underlying disease and elimination of the trigger mechanism. Additional treatment must be individualized, and generalizations are difficult to make. However, if the patient has low hemostatic factors and is actively bleeding or requires an invasive procedure, then replacement with the appropriate hemostatic factors should be tried. Heparin is indicated in patients with purpura fulminans and venous thromboembolism, but there is little evidence that heparin reverses organ dysfunction associated with DIC. In addition, heparin is also probably indicated in patients with retained dead fetus and hypofibrinogenemia prior to induction of labor, excessive bleeding associated with a giant hemangioma, and neoplastic disease, particularly promyelocytic leukemia. Although the use of heparin in acute forms of DIC remains controversial, the majority of studies suggest that it is not helpful. The role of antithrombin III (AT-III) concentrates is unknown, but they theoretically may be helpful when DIC is associated with very low AT-III levels, as is seen in liver disease.
Topics: Antithrombin III; Blood Transfusion; Disseminated Intravascular Coagulation; Fibrin Fibrinogen Degradation Products; Hemorrhage; Heparin; Humans; Purpura; Thromboembolism
PubMed: 7046845
DOI: No ID Found -
Clinical Pediatrics Jul 2024
Topics: Humans; Infant, Newborn; Purpura; Diagnosis, Differential; Male; Female
PubMed: 37646241
DOI: 10.1177/00099228231196744 -
Cold Spring Harbor Perspectives in... Jan 2013Hydrogen sulfide (sulfide, H(2)S) is a colorless, water-soluble gas with a typical smell of rotten eggs. In the past, it has been investigated for its role as a potent... (Review)
Review
Hydrogen sulfide (sulfide, H(2)S) is a colorless, water-soluble gas with a typical smell of rotten eggs. In the past, it has been investigated for its role as a potent toxic gas emanating from sewers and swamps or as a by-product of industrial processes. At high concentrations, H(2)S is a powerful inhibitor of cytochrome c oxidase; in trace amounts, it is an important signaling molecule, like nitric oxide (NO) and carbon monoxide (CO), together termed "gasotransmitters." This review will cover the physiological role and the pathogenic effects of H(2)S, focusing on ethylmalonic encephalopathy, a human mitochondrial disorder caused by genetic abnormalities of sulfide metabolism. We will also discuss the options that are now conceivable for preventing genetically driven chronic H(2)S toxicity, taking into account that a complete understanding of the physiopathology of H(2)S has still to be achieved.
Topics: Anti-Infective Agents; Brain Diseases, Metabolic, Inborn; Humans; Hydrogen Sulfide; Metronidazole; Models, Biological; Oxidation-Reduction; Purpura; Signal Transduction
PubMed: 23284046
DOI: 10.1101/cshperspect.a011437 -
Oncology (Williston Park, N.Y.) Sep 2011Tumor cells from malignancies of any type-carcinoma, sarcoma, lymphoma, leukemia-may cause systemic arteriolar and capillary obstructions. The high shear rates of blood... (Review)
Review
Tumor cells from malignancies of any type-carcinoma, sarcoma, lymphoma, leukemia-may cause systemic arteriolar and capillary obstructions. The high shear rates of blood passing through these obstructions result in fragmentation of the red cells and can cause severe anemia, described as microangiopathic hemolytic anemia (MAHA).The thrombi caused by these obstructions consume platelets and can lead to severe thrombocytopenia. MAHA (defined by fragmented red cells on the peripheral blood smear and evidence of hemolysis) and thrombocytopenia are the clinical features of syndromes described as thrombotic microangiopathies (TMAs). If a malignancy is not recognized as the cause of TMA, the diagnosis of thrombotic thrombocytopenic purpura (TTP) may be considered and plasma exchange, the essential treatment for TTP, may be initiated-a critical decision because this treatment carries a high risk of serious complications. This review describes the clinical features that should suggest a search for systemic malignancy as the cause of unexpected MAHA and thrombocytopenia. Recognition of a systemic malignancy is critical to the initiation of appropriate chemotherapy and avoidance of inappropriate use of plasma exchange treatment.
Topics: Humans; Neoplasms; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Thrombocytopenia
PubMed: 22010388
DOI: No ID Found -
Journal of the European Academy of... Dec 2021
Topics: COVID-19; Humans; Necrosis; Purpura; SARS-CoV-2; Skin
PubMed: 34309085
DOI: 10.1111/jdv.17562